These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24879578)

  • 1. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
    Kaiser U; Mendez SJ; Rønde T; Ullrich H
    J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VBID, the PPACA, and FREEE medications: Did politics trump the evidence about cost sharing?
    Fairman KA; Curtiss FR
    J Manag Care Pharm; 2012 Mar; 18(2):146-55. PubMed ID: 22380473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug licenses: a new model for pharmaceutical pricing.
    Goldman DP; Jena AB; Philipson T; Sun E
    Health Aff (Millwood); 2008; 27(1):122-9. PubMed ID: 18180487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reference Pricing Changes The 'Choice Architecture' Of Health Care For Consumers.
    Robinson JC; Brown TT; Whaley C
    Health Aff (Millwood); 2017 Mar; 36(3):524-530. PubMed ID: 28264955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential savings from an evidence-based consumer-oriented public education campaign on prescription drugs.
    Donohue JM; Fischer MA; Huskamp HA; Weissman JS
    Health Serv Res; 2008 Oct; 43(5 Pt 1):1557-75. PubMed ID: 18479406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Firm responses to targeted consumer incentives: Evidence from reference pricing for surgical services.
    Whaley CM; Brown TT
    J Health Econ; 2018 Sep; 61():111-133. PubMed ID: 30114564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Online drug pricing tools deserve more attention.
    Grunewald A
    J Manag Care Pharm; 2011 Mar; 17(2):176. PubMed ID: 21348550
    [No Abstract]   [Full Text] [Related]  

  • 9. The Daniel K. Inouye College of Pharmacy Scripts: Prescription Drug Pricing.
    Sumida WK; Taniguchi R; Juarez DT
    Hawaii J Med Public Health; 2016 Jan; 75(1):25-30. PubMed ID: 26870605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending.
    Brown TT; Robinson JC
    Health Econ; 2016 Jun; 25(6):740-9. PubMed ID: 25903495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does external reference pricing deliver what it promises? Evidence on its impact at national level.
    Kanavos P; Fontrier AM; Gill J; Efthymiadou O
    Eur J Health Econ; 2020 Feb; 21(1):129-151. PubMed ID: 31583483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the city to the bush: increases in patient co-payments for medicines have impacted on medicine use across Australia.
    Kemp A; Glover J; Preen DB; Bulsara M; Semmens J; Roughead EE
    Aust Health Rev; 2013 Feb; 37(1):4-10. PubMed ID: 23157851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Auditing the prescription drug consumer price index in a changing marketplace.
    Hicks AL; Berndt ER; Frank RG
    Health Econ; 2024 Aug; 33(8):1793-1810. PubMed ID: 38682795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESTIMATING WELFARE IN INSURANCE MARKETS USING VARIATION IN PRICES.
    Einav L; Finkelstein A; Cullen MR
    Q J Econ; 2010 Aug; 125(3):877-921. PubMed ID: 21218182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data on LEGO sets release dates and worldwide retail prices combined with aftermarket transaction prices in Poland between June 2018 and June 2023.
    Oczkoś W; Podgórski B; Szczepańska W; Boiński T
    Data Brief; 2024 Feb; 52():110056. PubMed ID: 38299105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does price-cap regulation work for increasing access to contraceptives? Aggregate- and pharmacy-level evidence from Colombia.
    Andia T; Mantilla C; Morales Á; Ortiz S; Rodríguez-Lesmes P
    Soc Sci Med; 2022 Oct; 311():115312. PubMed ID: 36063594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TSX Gives a Short Course in Health Economics: It's the Prices, Stupid!
    Evans RG
    Healthc Policy; 2010 Nov; 6(2):13-23. PubMed ID: 22043220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview and visual analysis of research on government regulation in healthcare.
    Qi M; Ren J
    Front Public Health; 2023; 11():1272572. PubMed ID: 38026398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments.
    Sullivan SD; Sullivan KD; Dabbous O; Garrison LP
    J Manag Care Spec Pharm; 2022 May; 28(5):566-572. PubMed ID: 35471069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.